Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

December 31, 2022

Conditions
Soft Tissue Sarcoma AdultHigh Grade Sarcoma
Interventions
DRUG

Anlotinib Hydrochloride

Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.

DRUG

Placebo Oral Tablet

Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.

Trial Locations (5)

200032

Fudan University Shanghai Cancer Center, Shanghai

200233

The Six People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai

310022

Zhengjiang Cancer Hospital, Hangzhou

510060

Cancer Hospital of Sun Yat-sen, Guangzhou

650118

Yunnan Cancer Hospital, Kunming

All Listed Sponsors
lead

Fudan University

OTHER

NCT03951571 - Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter